8. October 2024
Lymphatica Medtech closes €17.9M Series B funding round to drive Innovation in Lymphedema Treatment
Lausanne, October 8th, 2024 – Lymphatica Medtech SA, a clinical-stage company based in Lausanne, Switzerland, specialized in innovative treatments for lymphedema, has raised €17.9 million in Series B funding. This investment will accelerate the clinical development and validation of LymphoDrain, a breakthrough implantable device designed to treat lymphedema, a chronic vascular condition that currently has no cure and affects millions worldwide. First of its kind, LymphoDrain is easy to i
14. June 2023
Successful Exit for HTGF: FARCO-PHARMA acquires MedTech Startup Purenum GmbH
Cologne, 14 June 2023: FARCO-PHARMA, a company of the Klosterfrau Healthcare Group, is acquiring Purenum GmbH, which was founded in 2017. The MedTech start-up will operate as a wholly owned subsidiary of FARCO-PHARMA and will continue to drive forward its work in the area of research & development. The seed investor High-Tech Gründerfonds (HTGF), the investment company of BAB – Die Förderbank and FRIBA Investment have closely supported Purenum GmbH since 2018 and are selling thei
12. January 2023
MedTech Pitch Day 2023: Connecting Startups with Industry Leaders, Investors, and Decision-Makers
The MedTech Pitch Day, organised by HTGF, Dräger, B.Braun, Techniker Krankenkasse and the Health Innovation Port, is just around the corner. What can founders expect at the event and why should they definitely apply? We spoke to Anke Cassing, Principal at HTGF, and Jakob Lilienweiss, Investment Analyst at HTGF, to find out.
The MedTech Pitch Day will take place on March 29th in Berlin. Can you tell us more about the event and what founders can expect?
Anke: The event has develop
12. January 2023
Start-up stories: From science to business
Their first pitch deck didn’t contain a business slide. And there wasn’t any information on market potential. These were things that Dr Isabel Schellinger and Dr Uwe Raaz simply hadn’t thought of. After all, their focus was on their research, on the amazing opportunities made possible thanks to science, and on a medical solution to an aortic disorder in humans that they had developed. This is their passion and their field of expertise. Pitching to investors and founding a start-up were
